# Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)

> **NCT04942730** · PHASE2 · COMPLETED · sponsor: **St. Petersburg State Pavlov Medical University** · enrollment: 50 (actual)

## Conditions studied

- Leukemia, Acute Lymphoblastic
- Myeloid Leukemia, Acute
- Biphenotypic Acute Leukemia
- Lymphoblastic Lymphoma
- Myelodysplastic Syndromes
- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Bendamustine Hydrochloride
- **DRUG:** Busulfan
- **DRUG:** Cyclophosphamide
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Tacrolimus 5Mg Cap

## Key facts

- **NCT ID:** NCT04942730
- **Lead sponsor:** St. Petersburg State Pavlov Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-21
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04942730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04942730, "Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04942730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*